Despite excellent long-term results, routine postoperative radiotherapy of the regional lymphatics has been questioned as standard treatment in the management of stage I seminoma. Alternative strategies focus on sparing acute and late treatment morbidity, including carcinogenesis, without comprising cure rates. Surveillance strategies have shown to be a viable alternative, avoiding therapy for 75–80% of all patients; the same high level of survival is achieved by the use of primary chemotherapy and/or radiotherapy for recurrence. However, in comparison with routine irradiation, there is prolonged psychological stress for the patients, danger of extensive relapse and lower cost-effectiveness due to the necessity of intensive follow-up procedures. In nonrandomized studies, elective chemotherapy with single-agent carboplatin was equally effective regarding tumor control in short-term analyses. The question whether or not this treatment has advantages over radiotherapy in terms of treatment toxicity and long-term outcome is not proven and must be clarified in ongoing randomized prospective trials. During the last decade, the total radiation dose was gradually reduced by lowering treatment doses to 25 Gy. In addition, target volumes were restricted to the paraaortic lymph nodes, thus avoiding radiation damage to the remaining testicle. Even at follow-up periods in excess of 5 years the incidence of pelvic lymph node relapses remains below 4%. To date, limited low-dose radiotherapy following orchiectomy has to be considered as the standard method of treatment outside clinical trials.

This content is only available via PDF.
© 1999 S. Karger GmbH, Freiburg
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.